To observe the effect of Tiaobenjiangi Granule combined with Esomeprazole magnesium enteric-coated capsule in the treatment of gastroesophageal reflux cough (GERC).

From January 2022 to June 2023, 40 patients with GERC in the Gastroenterology, respiratory, otolaryngology, inpatient department of Traditional Chinese Medicine and outpatient department of the People's Hospital of Xinjiang Uygur Autonomous Region were collected for a randomized controlled prospective study. They were randomly divided into control group (20 cases) and treatment group (20 cases). The control group was given esomeprazole magnesium enteric-coated capsule alone, and the treatment group was given Tiaobingjiangi granules combined with esomeprazole magnesium enteric-coated capsule, the course of treatment was 4 weeks. The severity of GERC cough before and after treatment was assessed using the Cough Evaluation Test(CET), the GERD-Q scale was used to evaluate the gastroesophageal reflux, and the TCM symptoms, recurrence rate and safety were evaluated.

There was no significant difference in CET score, Gerd Q scale score and TCM symptom score between 2 groups before treatment (P>0.05). After 4 weeks of treatment, CET score in the treatment group was significantly lower than that in the control group, with statistical significance [(9.70±1.81) vs. (11.15±2.16) points, P<0.05]. The Gerd Q scale score of the treatment group was significantly lower than that of the control group, and the difference was statistically significant [(4.60±1.43) vs. (6.60±2.01) points, P<0.05]. The scores of TCM symptoms in the treatment group were significantly lower than those in the control group, and the difference was statistically significant (P<0.05). The recurrence rate was 10% in the treatment group and 40% in the control group, and the recurrence rate in the treatment group was significantly lower than that in the control group (P<0.05).There were no statistically significant differences in CET score, GERD-Q scale score and TCM symptoms between the two groups before treatment (P>0.05). In terms of improvement of gastroesophageal reflux symptoms, the treatment group was significantly better than the control group, and the differences were statistically significant (P<0.05). The treatment group was significantly better than the control group (P<0.05). The relief of cough, expectoration, acid reflux and belching in the treatment group was significantly better than that in the control group (P<0.05). The recurrence rate in the treatment group was 10%, and the effective rate in the control group was 40%, which was significantly lower in the treatment group than that in the control group (P<0.05).

Compared with esomeprazole magnesium enteric-coated capsule alone, Tiaobenjiangi granule combined with esomeprazole magnesium enteric-coated capsule had a better therapeutic effect on the gastric qi inversion syndrome of GERC.